Kaltenbach Patrick sold $1.3M of MTD

Kaltenbach Patrick (President and CEO) sold 942 shares of METTLER TOLEDO INTERNATIONAL INC/ (MTD) at $1425.00 ($1.34M total) on 2026-08-27.

Original reporting
SEC EDGAR · Kaltenbach Patrick
Published Aug 31, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 2:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MTD
Bearish
medium confidence
Mentioned
$MTD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MTDBearishLow
01

Why it matters

The CEO's sale may be interpreted as a bearish cue, but without context it remains ambiguous.

02

Market read

A sizable insider sell by the top executive, disclosed via SEC Form 4, provides fresh data for traders.

03

What to watch

Potential tax planning or personal liquidity needs may drive the transaction.

Relevance 6/10Novelty 5/10Timing: filed today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals about company outlook.

Company-level read

Ticker impact

$MTDBearishMedium confidence
Context

President and CEO Patrick Kaltenbach sold 942 shares for $1.34M on 2026-08-27, reducing his stake to 4,480 shares.

Expected impact

Possible modest downward pressure over the next few days.

Evidence & confidence

The sale size is notable for a large-cap executive, but no accompanying explanation was provided.

Market effects

Minimal impact on industrial equipment sector; only reflects insider activity.

None

Low

Counterpoint

The sale could be routine diversification rather than a negative signal.

Key entities

  • Patrick Kaltenbach

    President and CEO of Mettler Toledo International Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MTDHighAI 8/10

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway?

Mettler-Toledo's stock rose 25% despite biotech funding freeze. Management's 2026 EPS guidance of $47.70-$47.90 exceeds consensus, with 2027 guidance also above expectations. Analysts' average price target is $1,590, but some, like Jefferies, raised targets to $1,930. The company expects $900M in free cash flow, supporting an $875M share buyback. Growth drivers include pharmacopeia revisions and GLP-1 manufacturing. Investors should evaluate service revenue and hardware cycles.

$MTDMed

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway? By Investing.com RSS CTA

Mettler-Toledo International (MTD) has risen 25.2% in two months, defying a biotech funding slowdown. The company, a key supplier of precision lab instruments, benefits from regulatory requirements in commercial drug production. Q3 results showed $1.09B revenue, $12.57 adjusted EPS, and strong margins. Management's 2026-2027 EPS guidance exceeds Wall Street estimates, with free cash flow supporting share buybacks.

$MTDMedAI 8/10

What Mettler-Toledo International (MTD) Said on Its Q3 Earnings Call

Mettler-Toledo (MTD) reported Q3 gross margin expansion to 59.8% and adjusted operating profit growth of 8%. The company raised its 2026 sales growth forecast to 5% and issued 2027 guidance, expecting 5% sales growth and adjusted EPS of $52.50-$53.50. Management highlighted opportunities in automation, digitalization, and U.S. onshoring, with potential upside from AI-driven instrument upgrades.

$MTDMed

Jefferies raises Mettler-Toledo stock price target on solid growth

Jefferies raised its price target for Mettler-Toledo (MTD) to $1,930, citing strong Q3 results with 6% local currency growth and improved 2026 outlook. The stock trades near its 52-week high, up 26.5% in six months. MTD reported Q3 adjusted earnings of $12.57 per share and revenue of $1.09 billion, both exceeding estimates. The company provided initial 2027 guidance with 5% growth and EPS of $52.50-$53.50, above consensus.